CINVANTI Drug Patent Profile

Which patents cover Cinvanti, and what generic alternatives are available?

Cinvanti is a drug marketed by Heron Theraps Inc and is included in one NDA. There are thirteen patents protecting this drug and one Paragraph IV challenge.

This drug has nine patent family members in five countries.

The generic ingredient in CINVANTI is aprepitant. There are twenty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the aprepitant profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cinvanti

A generic version of CINVANTI was approved as aprepitant by SANDOZ on September 24^th, 2012.

Summary for CINVANTI

International Patents:	9
US Patents:	13
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	87
Patent Applications:	3,349
Drug Prices:	Drug price information for CINVANTI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CINVANTI
What excipients (inactive ingredients) are in CINVANTI?	CINVANTI excipients list
DailyMed Link:	CINVANTI at DailyMed

See drug prices for CINVANTI

Pharmacology for CINVANTI

Drug Class	Substance P/Neurokinin-1 Receptor Antagonist
Mechanism of Action	Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers Cytochrome P450 3A4 Inhibitors Neurokinin 1 Antagonists

Paragraph IV (Patent) Challenges for CINVANTI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CINVANTI	Intravenous Emulsion	aprepitant	130 mg/18 mL	209296	1	2022-04-29

US Patents and Regulatory Information for CINVANTI

CINVANTI is protected by thirteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes	9,808,465
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes	9,974,793		Y
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes	9,561,229		Y
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes	10,500,208		Y
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes	9,974,742		Y
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes	10,953,018
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes	9,974,794		Y

EU/EMA Drug Approvals for CINVANTI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Emend	aprepitant	EMEA/H/C/000527Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy.	Authorised	no	no	no	2003-11-11

International Patents for CINVANTI

See the table below for patents covering CINVANTI around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2022092040	アプレピタントのエマルジョン製剤
European Patent Office	3193830
World Intellectual Property Organization (WIPO)	2016044784
Japan	2022092040
South Korea	20170056575	아프레피탄트의 에멀젼 제형 (EMULSION FORMULATIONS OF APREPITANT)
China	106852118	阿瑞吡坦乳剂制剂 (Emulson formulations of aprepitant)
China	106852118

Supplementary Protection Certificates for CINVANTI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0734381	04C0010	France		PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111
0734381	PA2004002	Lithuania		PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
0734381	PA2004002,C0734381	Lithuania		PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
0748320	SPC/GB08/021	United Kingdom		PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
0748320	08C0019	France		PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
0734381	3/2004	Austria		PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
0734381	SPC/GB04/011	United Kingdom		PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113

CINVANTI (aprepitant) Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

What is CINVANTI’s market position in the antiemetic space?

CINVANTI is an intravenous (IV) formulation of aprepitant (NK1 receptor antagonist) marketed by Heron Therapeutics (U.S.) for chemotherapy-induced nausea and vomiting (CINV), including use with other agents for CINV prophylaxis. It competes inside the broader antiemetic regimen used around emetogenic chemotherapy, where market share hinges on guideline inclusion, formulary access, and the ability to reduce breakthrough symptoms in day-of-chemotherapy settings.

Commercial reality: NK1 antagonists remain a core component of multi-day antiemetic prophylaxis for highly emetogenic chemotherapy (HEC) and are typically paired with a 5-HT3 antagonist and dexamethasone. CINVANTI’s differentiation is its IV administration and its role in regimens where IV access is preferred at initiation.

Who are the competitors and how do they compare?

CINVANTI competes primarily with other NK1 antagonists and, indirectly, with agents used to replace/augment NK1 coverage in protocols.

Core competitor set (commercially relevant)

• Emend (aprepitant oral): Same active moiety as CINVANTI but administered orally, supporting multi-day regimens where oral dosing is feasible.
• Akynzeo (netupitant/palonosetron): NK1 antagonist combination product used in single-day and multi-day strategies depending on regimen and label.
• Aloxi (palonosetron) and 5-HT3 agents: Not NK1 antagonists but compete within the antiemetic stack where formulary constraints affect uptake.

Market dynamic: regimen economics and administration route

• IV-first workflows favor IV products at day 1 of chemotherapy when oral intake is constrained.
• Oral availability shifts preference toward oral aprepitant (Emend) or combination NK1 approaches when patient throughput and pharmacy workflow drive switching decisions.

What demand drivers move CINVANTI volume?

1. Chemotherapy incidence and regimen mix
   • Uptake increases with the number of patients receiving HEC and proportionally emetogenic chemotherapy where guideline-based NK1 inclusion is routine.
2. Protocol intensity and breakthrough risk management
   • Hospitals and cancer centers optimize prophylaxis based on prior CINV history and regimen emetogenicity categories.
3. Formulary access and contracting
   • CINVANTI performance is driven by national and regional contracting terms, GPO inclusion, and pharmacy buy-and-bill patterns for IV oncology supportive care.
4. Switching behavior between IV and oral
   • Because CINVANTI shares the same active class as Emend, switching is commonly triggered by:
     • patient ability to take oral dosing,
     • IV administration preference at initiation,
     • and payer/provider contracting relative to oral NK1 options.

What is the payer-and-provider buying logic behind CINVANTI?

Buying decisions in oncology supportive care typically rest on:

• Clinical pathway fit (day 1 prophylaxis and multi-day regimen alignment),
• Administrative workflow (IV preparation, availability, and order timing),
• Net pricing (rebates and contracting),
• Inventory risk and drug wastage tolerance in infusion settings.

CINVANTI’s value proposition is anchored to its IV delivery and its role in a standard NK1-inclusive prophylaxis approach.

How has CINVANTI’s financial trajectory evolved (revenue, ownership, and growth constraints)?

CINVANTI has followed a pattern common to niche IV supportive care products: revenue growth is typically constrained by (1) limited label population compared with broader symptom-control markets, and (2) competition from oral formulations and combination NK1 products.

Ownership and commercialization context

CINVANTI is marketed in the U.S. by Heron Therapeutics (brands and product commercialization). Heron’s strategic shifts have influenced investment and go-to-market intensity, affecting adoption speed across oncology centers. Heron’s broader operating environment also affects how aggressively the brand is expanded via payer contracting and hospital formulary development.

Financial shape: a supportive-care profile

Supportive care brands like CINVANTI usually show:

• steady demand tied to chemotherapy volumes,
• episodic step-changes when payer policy or major GPO contracts adjust,
• limited upside versus oncology therapeutics, since prescribers rarely “upgrade” beyond guideline-based NK1 coverage unless breakthrough CINV drives regimen intensification.

What matters for trajectory assessment

For CINVANTI, the key measurable trajectory signals are:

• Net sales trends by quarter
• Volume shifts between IV and oral aprepitant
• Managed care restriction versus continued formulary placement
• Inventory and replacement cycles in infusion centers

The next section provides a practical framework for interpreting financial trajectory drivers through business metrics. It does not rely on speculative forward projections.

What are the measurable business levers behind CINVANTI sales performance?

1) Formulary placement and contract position

• Health systems decide whether CINVANTI is a preferred IV NK1 or a backup option.
• In multi-NK1 markets, IV product uptake depends on how tightly the system restricts alternatives at infusion initiation.

2) Competition from oral aprepitant and NK1 combinations

• CINVANTI is vulnerable when:
  • patients and centers can complete oral dosing after day 1,
  • combination NK1 products gain coverage as “simpler regimen” options.
• It benefits when:
  • IV administration is required for day 1 prophylaxis,
  • infusion timing makes IV preferred for workflow.

3) Payer policy and utilization management

• Prior authorization and step therapy are common in supportive care where plan formularies narrow NK1 choices.
• Coverage expansions typically translate into faster pull-through through oncology infusion prescribing.

4) Hospital purchasing behavior

• Buy-and-bill patterns at infusion centers link uptake to the center’s reimbursement economics and internal procurement strategy.

How does CINVANTI compare on label and regimen utility versus competing NK1 products?

From a utilization standpoint, the decision usually reduces to:

• Does the patient need IV dosing at initiation?
• Does the center prefer a single IV product versus switching to oral later?
• Does the plan cover the IV NK1 without restrictive PA?

CINVANTI’s operational fit is strongest when day 1 IV prophylaxis is needed and the regimen requires NK1 coverage for HEC and similarly emetogenic chemotherapy.

What timeline markers likely affected CINVANTI’s financial path?

CINVANTI’s financial trajectory would be expected to respond to three event categories:

1. Regulatory or label updates (expansion in regimen inclusion or dosing instructions)
2. Competitive launches and contracting shifts (NK1 product availability, combination uptake)
3. Ownership/commercial resource changes (go-to-market intensity, payer contracting strategy)

Without pulling in brand-level financial numbers here, the actionable takeaway for trajectory interpretation is that CINVANTI’s sales movement should track chemotherapy supportive care contracting and utilization management more than it tracks one-off physician prescribing preferences.

What does the market mean for future profitability and cash flow?

The brand economics for CINVANTI are shaped by:

• competitive discounting in IV supportive care,
• rebate intensity from managed care contracts,
• the narrowness of its clinical use profile,
• and the risk of switching to oral NK1 strategies where feasible.

High-level expectation: profitability tends to compress when payer coverage tightens and when oral or combination NK1 products win formulary preferences for the same regimen need.

Key Takeaways

• CINVANTI operates inside the guideline-driven NK1 segment for CINV prophylaxis, where IV administration route and day 1 workflow fit drive adoption.
• Competitive pressure comes mainly from oral aprepitant and NK1 combinations that can simplify dosing and gain formulary preference through contracting.
• Financial trajectory is typically governed by formulary access, payer utilization management, and health-system switching behavior between IV and oral NK1 strategies.
• Profitability is sensitive to net pricing and rebate intensity in oncology supportive care contracts.

FAQs

1) Is CINVANTI an NK1 antagonist, and what is its clinical role?

Yes. CINVANTI is an IV aprepitant product used in CINV prophylaxis regimens that include NK1 antagonism as part of combination therapy.

2) What products most directly compete with CINVANTI?

Oral aprepitant products (same active moiety) and NK1-containing combination products that cover CINV prophylaxis needs, plus indirect competition from 5-HT3 antagonists in regimen selection.

3) Why does IV administration matter for CINVANTI demand?

IV administration supports day 1 prophylaxis in infusion settings and can align with patient situations where oral dosing is not preferred or not timely.

4) What drives quarterly sales changes for IV supportive care brands like CINVANTI?

Contracting changes, formulary inclusion or restrictions, utilization management, and switching between IV and oral NK1 options.

5) How should investors evaluate CINVANTI’s financial trajectory without relying on top-line narratives?

Track net sales trend shape alongside formulary/PA changes, biopsy-like signals from infusion utilization, and the relative uptake shift between IV aprepitant and oral/combination NK1 strategies.

---

References

[1] CINVANTI (aprepitant) U.S. Prescribing Information. Heron Therapeutics.
[2] FDA approval and product labeling materials for CINVANTI (aprepitant) and relevant NK1 antagonist labeling context. U.S. Food and Drug Administration.
[3] NCCN Guidelines for Antiemesis (CINV prophylaxis regimen frameworks and NK1 antagonist inclusion). National Comprehensive Cancer Network.